NEW YORK--(BUSINESS WIRE)--Medidata Solutions (Nasdaq: MDSO), a leading global provider of hosted clinical development solutions, today announced Switzerland-based NovImmune has selected Medidata’s Trial Planning product suite to support the development of its diverse pipeline of biologics for immune-related disorders. NovImmune has already utilized Medidata Grants Manager™ and CRO Contractor™ for a Phase II type I diabetes trial involving 160 patients and 75 sites in 12 countries, and is also incorporating Medidata Designer™ into its clinical development process.
